Molecular Cell, Volume 50
Supplemental Information

Neurodegeneration-Associated Protein Fragments as Short-Lived Substrates of the N-End Rule Pathway

Christopher S. Brower, Konstantin I. Piatkov, and Alexander Varshavsky
**Figure S1.** The mammalian N-end rule pathway. N-terminal residues are indicated by single-letter abbreviations for amino acids. A yellow oval denotes the rest of a protein substrate. E3 ubiquitin (Ub) ligases of the N-end rule pathway are called N-recognins.

(A) The Arg/N-end rule pathway. “Primary”, “secondary” and “tertiary” denote mechanistically distinct subsets of destabilizing N-terminal (Nt) residues. C* denotes oxidized N-terminal Cys, either Cys-sulfinate or Cys-sulfonate, produced *in vivo* by reactions that require nitric oxide (NO) and oxygen. Oxidized N-terminal Cys is Nα-terminally arginylated (Nt-arginylated) by *ATE1*-encoded isoforms of arginyl-tRNA-protein transferase (R-transferase), which also arginylates N-terminal Asp (D) and Glu (E). N-terminal Asn (N) and Gln (Q) are deamidated by the *NTAN1*-encoded NtN-amidase and the *NTAQ1*-encoded NtQ-amidase,
respectively. In addition to their binding sites that recognize primary destabilizing N-terminal residues, the UBR1, UBR2, UBR4 and UBR5 (EDD) N-recognins contain binding sites for substrates (denoted by a larger oval) with internal (non-N-terminal) degradation signals. Polyubiquitylated Arg/N-end rule substrates are processively destroyed to short peptides by the 26S proteasome. Hemin (Fe$^{3+}$-heme) binds to R-transferase, inhibits its Nt-arginylation activity and accelerates its in vivo degradation. Hemin also binds to UBR-type N-recognins and alters them functionally, in ways that remain to be understood. Regulated degradation of specific proteins by the Arg/N-end rule pathway mediates the sensing of heme, NO, oxygen, and short peptides; the elimination of misfolded proteins; the regulation of DNA repair; the fidelity of chromosome cohesion/segregation; the signaling by G proteins; the control of peptide import; the regulation of apoptosis, meiosis, viral and bacterial infections, fat metabolism, cell migration, actin filaments, cardiovascular development, spermatogenesis, neurogenesis, and memory; and the functioning of adult organs, including the brain, muscle, testis and pancreas ((Brower and Varshavsky, 2009; Caprio et al., 2010; Choi et al., 2010; Dougan and Truscott, 2011; Eisele and Wolf; 2008; Graciet and Wellmer, 2010; Heck et al., 2010; Hu et al., 2008; Hwang et al., 2010a; Hwang et al., 2010b; Hwang et al., 2011; Kurosaka et al., 2010; Matta-Camacho et al., 2010; Mogk et al., 2007; Nillegoda et al., 2010; Piatkov et al., 2012a; Piatkov et al., 2012b; Tasaki et al., 2012; Varshavsky, 2011; Wang et al., 2009; Wang et al., 2011; Zhang et al., 2010), and refs. therein).

(B) The Ac/N-end rule pathway. Although it is virtually certain that this pathway is present in all eukaryotes (Varshavsky, 2011), it has been characterized, thus far, only in *S. cerevisiae* (Hwang et al., 2010b). This diagram illustrates the mammalian Ac/N-end rule pathway through extrapolation from its *S. cerevisiae* version. Red arrow on the left indicates the removal of N-terminal Met by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a residue at position 2 is nonpermissive (too large) for MetAPs. If the retained N-terminal Met or N-terminal Ala, Val, Ser, Thr, and Cys are followed by acetylation-permissive residues, the above N-terminal residues are Nt-acetylated by ribosome-associated Nt-acetylases (Arnesen et al., 2009). The resulting N-degrons are called Ac/N-degrons, to distinguish them from other N-degrons (Hwang et al., 2010b; Varshavsky, 2011). Although the second-position Gly or Pro residues can be made N-terminal by MetAPs, few proteins with N-terminal Gly or Pro are Nt-acetylated (Arnesen et al., 2009). The term “secondary” refers to the Nt-acetylation of a destabilizing N-terminal residue before a protein can be recognized by a cognate N-recognin.

(C) The Ub reference technique (URT), derived from the Ub fusion technique (Piatkov et al., 2012a; Suzuki and Varshavsky, 1999; Varshavsky, 2005). Cotranslational cleavage of a URT-based fusion by deubiquitylases produces, at the initially equimolar ratio, a test protein with a desired N-terminal residue and a “reference” protein such as 5DHFR-UbR$^{48}$, a flag-tagged derivative of the mouse dihydrofolate reductase. In URT-based pulse-assays, the labeled test protein is quantified by measuring its level relative to the levels of a stable reference at the same time point. In addition to being more accurate than pulse-chases without a stable reference, URT assays make it possible to detect and measure the degradation of a test protein during the pulse, i.e., before the chase (Piatkov et al., 2012a; Varshavsky, 2005).

Figure S1 refers to Figures 1 and 3.
Figure S2. Evolutionary conservation of the destabilizing nature of P1’ residues in the cleavage sites that yield the natural fragments of TDP43, α-Synuclein, and Tau. (A P1’ residue becomes N-terminal upon protein cleavage.)

(A) Domain organization of TDP43. Arrowheads indicate the cleavage sites 1, 2 and 3 in full-length TDP43 that yield the natural C-terminal fragments isolated from protein aggregates in human FTLD-TDP brains (see Figure 1 and the main text) (Igaz et al., 2009; Nonaka et al., 2009;
Pesiridis et al., 2011; Wang et al., 2012). The identity of protease(s) that generates these TDP43 fragments is unknown. The indicated residue numbers, including those of P1’ residues (these residues are in color and in a larger font size), are of the full-length human TDP43. Note the complete conservation of the P1’ Asp (D) residues at the cleavage sites 2 and 3 (positions 219 and 247). Note also the “drift-with-constraint” evolutionary pattern of the P1’ residues in the cleavage site 1 (see the main text). Specifically, a P1’s residue is Arg (R) in most species but Gln (Q), another destabilizing residue, in the mouse, rat, and chicken.

(B) Domain organization of human α-synuclein. Arrowhead indicates the metalloprotease cleavage site (Choi et al., 2011). (Metalloproteases are usually extracellular but can occur in the cytosol as well (Cauwe and Opdenakker, 2010).) For notations, see A. Analogously to the evolutionary pattern observed with P1’ residues in the cleavage site 1 of TDP43 in A, most P1 residues in the cleavage site of α-synuclein are Gln (Q), at position 79 of the human α-synuclein. However, some mammals (such as guinea pigs), some frogs (such as Xenopus laevis), and some fishes (such as pikes) contain His at the P1’ position of their α-synucleins (Figure S2B). Both N-terminal Gln and His are destabilizing residues (Figure S1A). Yet another informative aspect of evolution of the P1’ residue of α-synuclein is that all changes of the predominant Gln at the P1’ position (equivalent to position 79 in human α-synuclein) in separate vertebrate lineages (mammals, frogs, fishes) were invariably to His, rather than to another residue. A plausible explanation stems from the fact that the CAA/CAG codons for Gln differ from the CAT/CAC codons for His by one nucleotide. A similar interpretation is also relevant to the evolutionary change of a P1’s residue at position 208 in human TDP43 (panel A): the alteration from Arg to Gln at the P1’ position of full-length TDP43 in vertebrates involved a single-base transition between the CGG Arg codon and the CAG Gln codon.

(C) Domain organization of the human Tau-2N isoform. Two arrowheads indicate the calpain cleavage sites. In the first of them, the P1’ residue of human Tau is Glu (E), at position 3. The third cleavage site is specific for caspasases, in particular caspase-6, with the P1’ residue being His (H), at position 14 (Spires-Jones et al., 2011; Zilka et al., 2012). In yet another example of the drift-with-constraint evolutionary pattern of P1’ residues seen above with TDP43 and α-synuclein (panels A and B), the P1’ residue at position 3 of the calpain cleavage site of Tau-2N is Gln in humans, horses, rats, chickens and other vertebrates, but is Asp in mice. Both His, Glu and Asp are destabilizing residues (Figure S1A). Caspasases have been shown to cleave human Tau-2N between Asp13 and His14, and also 19 residues upstream of its C-terminus, at Asp421-Ser422, with the former cleavage mediated by at least caspase-6 ((Horowitz et al., 2004) and refs. therein). The Asp13-His14 cleavage produces the N-terminally truncated Tau bearing N-terminal His, a destabilizing residue. The resulting His14-Tau is yet another (predicted) physiological substrate of the Arg/N-end rule pathway. All but one among the examined mammalian Tau sequences has His at the P1’ position (this residue becomes N-terminal after caspase cleavage). The only exception, rat Tau, has Gln (Q) at this position, but both His and Gln are destabilizing residues, a recurrent example of the drift-with-constraint pattern of P1’ residues described above for other neurodegeneration-associated fragments.

The evolutionary retention of a destabilizing nature of a P1’ residue in a precursor of a caspase-generated fragment of any protein (not only of Tau) is noteworthy for an additional and independent reason as well. More than 90% of caspase cleavage sites in cellular proteins contain, at their P1’ positions, small residues such as Gly, Ser, Thr and Ala (Crawford and Wells, 2011; Pop and Salvesen, 2009). These residues are not recognized by the Arg/N-end rule pathway (Figure S1A). Thus, remarkably, the destabilizing P1’ residues His or Gln in the precursors of
caspase-generated X14-Tau fragments in different mammals (let alone the evolutionary conservation of these residues) would not be expected on a priori grounds, given the major preponderance of smaller P1’ residues in caspase substrates at large. Together with our previous findings (Piatkov et al., 2012a; Varshavsky, 2012), these results strongly suggest adaptive (fitness-increasing) origins of the observed destabilizing P1’ residues in the precursors of the TDP43, α-synuclein, and Tau fragments examined in the present work.

Figure S2 refers to Figures 1, 2 and 3.

Figure S3. The Natural C-Terminal Fragment of Human Tau-1N As a Short-Lived Substrate of the Arg/N-End Rule Pathway.

(A) Domain organization of human Tau-1N. Arrowheads indicate the calpain cleavage sites. See also Figure 3D-F and the main text.

(B) The N-terminus-proximal cleavage site is indicated by an arrowhead, with the P1’ Glu (E) residue shown in red. The X3-Tau-1N95 fragments, produced from 5DHFR-UbR48-X3-Tau-1N95 fusions (X= Glu, Val) in reticulocyte extract, were assayed for degradation as described in the legend to Figure 1B.

(C) Quantification of B using the reference protein 5DHFR-UbR48.

Figure S3 refers to Figure 3D, E.
Figure S4. 35S-Pulse-Chase Assays in *S. cerevisiae* with URT fusions encoding X-Aβ42<sup>13myc</sup>.

(A) The fDHFR-Ub<sup>R48</sup>-Asp-Aβ42<sup>13myc</sup> URT-type fusion, was expressed in wt, *ate1Δ*, or *ubr1Δ* *S. cerevisiae* as described in Supplemental Experimental Procedures. The fusion’s cotranslational cleavage by deubiquitylases produced the reference fDHFR-Ub<sup>R48</sup> and the test protein Asp-Aβ42<sup>13myc</sup>. These proteins were pulse-labeled with 35S-Met/Cys for 5 min at 30°C, followed by the chase for 0, 10 and 20 min, preparation of cell extracts, immunoprecipitation with anti-myc/anti-flag antibodies, SDS-PAGE and autoradiography. Lane 1, *S. cerevisiae* were transformed with vector alone (negative control). Lanes 2-4, Asp-Aβ<sub>42</sub><sup>13myc</sup> and fDHFR-Ub<sup>R48</sup> in *ate1Δ* cells lacking Nt-arginylation. Lanes 5-7, same as lanes 2-4 but in wt *S. cerevisiae*. Lanes 8-10, the same as lanes 2-4 but in *ubr1Δ* cells lacking the N-recognin of the Arg/N-end rule pathway. The bands of 35S-labeled Asp-Aβ42<sup>13myc</sup> and fDHFR-Ub<sup>R48</sup> are indicated on the left.

(B) Quantification of A.

(C) Same as in A but fDHFR-Ub<sup>R48</sup>-Met-Aβ42<sup>13myc</sup> whose in vivo cleavage by deubiquitylases yields Met-Aβ42<sup>13myc</sup>.

(B) Quantification of C.

Figure S4 refers to Figures 4 and 5.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Miscellaneous Reagents

Cycloheximide was from Sigma (St. Louis, MO). Human cDNAs encoding proteins examined in the present work were from OpenBiosystems (Huntsville, AL). MG132 (BML-PI102-0005) and clasto-Lactacystin β-Lactone (BML-PI108-0100) were from EnzoLife Sciences (Farmingdale, NY). Epoxomicin (E3652), Thiorphan (T6031), Racecadotril (SML0043), Phosphoramidon (R7385) and Verapamil (V4629) were from Sigma. The following antibodies were used: anti-FLAG M2 (Sigma, F1804), anti-c-Myc (Sigma, C3956), anti-Beta-Amyloid (4G8) (Covance, SIG-39220), anti-Amyloid Precursor Protein (Calbiochem, 171610); and affinity-purified polyclonal antibody to mouse Ate1 (Hu et al., 2005). The following reagents were used for immunoprecipitation: anti-flag M2 Magnetic Beads (Sigma, M8823) and EZview Red anti-c-Myc affinity gel (Sigma, E6654). Detection was carried out using HRP-conjugated goat anti-Rabbit (BioRad, 170-6515) or anti-mouse (BioRad, 170-6516) antibodies and either ECL Prime Western Blotting Detection System (GE Healthcare, UK) or SuperSignal West Femto reagents (Thermo Scientific, Rockford, IL), according to manufacturers’ protocols.

5xFAD mice were obtained from The Jackson Laboratories (JAX stock number 006554). Postmortem human brain tissue was obtained from the Harvard Brain Tissue Resource Center.

Plasmids, cDNAs, and Primers

DH5α E. coli (Invitrogen) was used for cloning and maintaining plasmids. Phusion High-Fidelity DNA polymerase (New England Biolabs) was used for polymerase chain reaction (PCR). Sequences of all constructed plasmids were verified by DNA sequencing.

Asp-Aβ42\textsuperscript{13myc}. cDNA encoding human Aβ42 sequence (Figure 4A) was amplified by PCR using a set of overlapping forward primers (CB302F, CB268F, CB269F, CB270F, and CB271F) and reverse primers (CB272R, CB273R, CB274R, and CB304R) (Table S2) whose assembled sequence contained DNA encoding human Aβ42. The resulting DNA fragment was inserted into pFA6a-13Myc-kanMX6 (Table S1) using Sac\textsc{II}/Sma\textsc{I} sites to produce pCB253. The Aβ42\textsuperscript{13myc}-coding sequence was removed from pCB253 using Sac\textsc{II}/EcoR\textsc{I} and inserted into Sac\textsc{II}/EcoR\textsc{I}-cut pCH280 (Hwang et al., 2009) to produce pCB255, a low copy plasmid which was used to express \textbf{f}DHFR-Ub\textsuperscript{R48}-Asp-Aβ42\textsuperscript{13myc} from the \textbf{P}\textsuperscript{MET25} promoter in \textit{S. cerevisiae}. \textbf{f}DHFR-Ub\textsuperscript{R48}–X–Aβ42\textsuperscript{13myc} fusions (X=Met, Val, Arg-Asp) were constructed by amplifying the human Aβ42-coding DNA fragment with the following sets of primers: CB313F and CB304R (Met-Aβ42\textsuperscript{13myc}); CB314F and CB304R (Val-Aβ42\textsuperscript{13myc}); CB316F and CB304R (Arg-Asp-Aβ42\textsuperscript{13myc}). The resulting fragments were cut with Sac\textsc{II} and \textsc{Sma}, and cloned into Sac\textsc{II}/\textsc{Sma}–cut pCB255 to produce the plasmids pCB255, pCB282, pCB284, and pCB285 (Table S1). For \textsuperscript{35}S-pulse-chase URT-based assays in rabbit reticulocyte extract, the DNA fragment encoding \textbf{f}DHFR-Ub-Asp-Aβ\textsuperscript{13myc} was removed from pCB255 by Hind\textsc{III} digestion and inserted into Hind\textsc{III}-cut pcDNA3.0 (Invitrogen) to produce pCB268 (Table S1).

\textbf{TDP43}. The human \textit{Tdp43} cDNA was obtained from OpenBiosystems (ID: LIFESEQ2505218). DNA fragments encoding X208-TDP43 C-terminal fragments (X=Arg, Met, Gln, and Glu) were constructed by amplification, using the following sets of primers: CB320F and CB327R (Arg208-TDP43); CB321F and CB327R (Met208-TDP43); CB322F and CB327R (Gln208-TDP43); and CB323F and CB327R (Glu208-TDP43) (Table S2). C-terminal flag tags were added by sequential PCR extension using the above forward primers with, at first, CB275R, and then CB280R. The resulting PCR products, which encoded X208-TDP43\textsuperscript{f}, were
cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB322, pCB323, pCB324, and pCB325 (Table S1). DNA encoding X219-TDP43\(^f\) C-terminal fragments (X=Asp, Met, Val, and Arg-Asp) were amplified from pCB323 using the following sets of primers: CB330F and CB329R (Asp219-TDP43\(^f\)); CB331F and CB329R (Met219-TDP43\(^f\)); CB332F and CB329R (Val219-TDP43\(^f\)); and CB333F and CB329R (Arg-Asp219-TDP43\(^f\)). DNA encoding X247-TDP43\(^f\) C-terminal fragments (X=Asp, Met, Val, and Arg-Asp) were amplified from pCB323 using the following sets of primers: CB334F and CB329R (Asp247-TDP43\(^f\)); CB335F and CB329R (Met247-TDP43\(^f\)); CB336F and CB329R (Val247-TDP43\(^f\)); and CB337F and CB329R (Arg-Asp247-TDP43\(^f\)). The resulting PCR products, which encoded either X219-TDP43\(^f\) or X247-TDP43\(^f\), were cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB326-pCB333 (Table S1).

For mammalian expression using the weaker (relative to the P\(_{CMV}\) promoter) P\(_{SV40}\) promoter, DNA fragments encoding the DHFR-Ub-X-TDP43\(^f\) fusions in pcDNA3.0-based plasmids (containing the P\(_{CMV}\) promoter) were used to replace the luciferase reporter in pGL3-Control plasmid (Promega) after digestion with HindIII/XbaI.

To construct the plasmid pCB400, used in \textit{in vivo} aggregation assays (Figure 2C-E), DNA encoding mCherry was amplified from pKP551 (Table S1) using primers CB383F and CB384R, and the resulting PCR product was used to replace the DHFR moiety in pCB338 after digestion with HindIII/AgeI.

\textbf{α-Synuclein.} The human α-synuclein cDNA was obtained from OpenBiosystems (ID: 5287266). DNA encoding X\(_{79}\)-αSyn\(^f\) (X= Gln and Val) were constructed by amplification with the following sets of primers: CB364F and CB367R (Gln79-αSyn); and CB365F and CB367R (Val79-αSyn). The resulting DNA fragments were cut with SacII/XbaI, and cloned into SacII/XbaI-cut pCB268, generating the plasmids pCB347 and pCB348 (Table S1).

\textbf{Tau.} The human Tau-1N cDNA (lacking exon 3) was obtained from OpenBiosystems (ID: LIFESA6770882). DNA encoding X\(^3\)-Tau-1N\(^{95\text{f}}\) (X= Glu and Val) were constructed by amplification with the following sets of primers: CB373F and CB377R (Glu3-TauN1) and CB375F and CB377R (Val3-TauN1). CB377 encoded the C-terminal sequence PGSDYKDDDDK, containing the linker and the flag epitope. Human Tau-2N cDNA (containing exon 3) was obtained by a three-step PCR strategy whereby the N-terminal portion of the Tau\(^3\)-coding fragment was amplified using the above forward primers and CB379R (whose 5’-proximal region is the reverse complement of the 5’-region of CB380F). The C-terminal portion of the Tau\(^3\)-coding fragment was amplified using CB380F (whose 5’-proximal region is the reverse complement of the 5’-region of CB379R) and CB377R. The entire Tau-2N\(^3\)-coding fragment was amplified using the overlapping N- and C-terminal fragments as templates in a final PCR step that employed CB373F and CB377R (Glu3-Tau-2N\(^{124}\)) as well as CB375F and CB377R (Val3-Tau-2N\(^{124}\)). The resulting DNA fragments were cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB383, pCB385, pCB386, and pCB388 (Table S1).

**In Vitro Transcription-Translation-Degradation Assay**

The TNT T7 Coupled Transcription/Translation System, a version of the Promega’s rabbit reticulocyte extract preparation in which the main components of the system were supplied separately, was used to carry out transcription-translation-degradation assays. Reaction samples were prepared according to the manufacturer’s instructions. Nascent proteins in reticulocyte extract were pulse-labeled with \(^{35}\)S]-methionine (0.55 mCi/ml, 1,000 Ci/mmol,
MP Biomedicals) for 10 min at 30°C, in the total volume of 30 µl. The labeling was quenched by the addition of cycloheximide and unlabeled methionine, to the final concentrations of 0.1 mg/ml and 5 mM, respectively. Samples were withdrawn at indicated timepoints of a chase and the reactions were terminated by the addition of 0.1 ml of TSD buffer (1% SDS, 5 mM dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4) and snap-freezing in liquid nitrogen. Samples were then heated at 95°C for 10 min, diluted with 10 volumes of TNN buffer (0.5 % NP-40, 0.25 M NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.4), containing the “complete protease-inhibitor mixture” (Roche), clarified by centrifugation at 20,000g for 5 min and immunoprecipitated using 5 µl of beads with an immobilized antibody, either anti-flag M2 Magnetic Beads or EZview Red anti-c-Myc affinity gel. The immunoprecipitates were incubated with rocking at 4°C for 3 hr, followed by 3 washes in TNN buffer, one wash in 10 mM Tris-HCl (pH 8.5), and resuspension in 20 µl of SDS-sample buffer. Samples were then heated at 95°C for 10 min and fractionated by SDS-4-15% PAGE, followed by autoradiography, using Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and quantification, using ImageQuant (GE Healthcare).

Cell Culture

Mouse NIH-3T3 and human HEK-293T cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Ate1−/− mouse embryonic fibroblasts (EFs) were described previously (Kwon et al., 2002). Cells were grown at 37°C in 5% CO₂ in DMEM medium supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA) and penicillin/streptomycin (100 units/ml) (Hyclone). Cells were transfected using Lipofectamine-2000 (Invitrogen) according to the manufacturer’s protocol.

In Vivo Degradation Assay

Human embryonic kidney-293T cells (~75% confluent) were transfected with 1 µg plasmid per 35-mm well using Lipofectamine-2000 according to the manufacturer’s protocol. Forty hours post-transfection cells were pulse-labeled for 15 min with [35S]L-methionine (0.1 mCi/ml, MP Biomedicals) in DMEM lacking Met and Cys. Labeling was quenched by the addition of cycloheximide (0.1 mg/ml) in complete DMEM (containing Met as well). Cells contained in an entire 35-mm well were lysed at the indicated timepoints of a chase by rapid scraping in 150 µl of TSD buffer (see above) and snap freezing in liquid nitrogen. Samples were then heated at 95°C for 10 min and diluted with 10 volumes of TNN buffer (see above) containing the “complete protease-inhibitor mixture” (Roche). Total 35S (in the 10% CCl₃COOH-insoluble fraction) in samples was then measured, and volumes were adjusted to equalize 35S among different samples. Thus prepared samples were immunoprecipitated by the addition of 5 µl of anti-flag M2 magnetic beads and incubation with rocking at 4°C for 3 hr. Immunoprecipitated proteins were then washed 3 times in TNN buffer and once in 10 mM Tris-HCl (pH 8.5), followed by resuspension in 20 µl of SDS-sample buffer, heating at 95°C for 10 min, SDS-4-15% PAGE, and autoradiography, with quantification as described above.

In Vivo Aggregation Assay

Poly-D-lysine (1 mg/ml)-coated coverslips were placed in 35-mm tissue culture dishes and 1.5 × 10⁵ mouse embryonic fibroblasts (NIH-3T3 or Ate1−/−) were seeded on top and grown until ~65% confluency. Cells were then transfected with 1 µg of pCB400 per plate, using Lipofectamine-2000. Twenty-four hrs after transfection, cells were fixed in 4% formaldehyde for 10 min at room temperature, and permeabilized in 0.5% Triton-X100 in PBS for 10 min at room
temperature. Coverslips were then washed three times in PBS, and blocked in 10% goat serum for 30 min. Coverslips were incubated with anti-flag M2 antibody (at 1/1000 dilution in 5% goat serum/PBS containing 0.1% Tween-20) for 2 hrs at 37°C in a humid environment, followed by three 5 min washes in PBS containing 0.1% Tween-20 and incubation with fluorescein-conjugated anti-mouse secondary antibody (Pierce, #31567) (at 1/200 dilution in 5% goat serum/PBS containing 0.1% Tween-20) for 1 hr at 37°C in a humid environment. Coverslips were again washed 3 times in PBS containing 0.1% Tween-20, and thereafter were mounted using Vectashield H-1500 mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). Thus processed coverslips were examined for fluorescence by mCherry, DAPI, and fluorescein-conjugated secondary anti-mouse antibody using Zeiss Axio Imager 2.

**Steady-State and Pulse-Chase Assays of X-Aβ4213myc in S. cerevisiae**

*S. cerevisiae* JD52 (MATa, trp1-Δ63, ura3–52, his3-Δ200, leu2–3112, lys2-801) and JD55 (ubr1Δ::HIS3 in JD52) were described previously(Ghislain et al., 1996). *S. cerevisiae* CHY21 (ate1Δ::KanMX6 in JD52) and CHY22 (ubr1Δ::HIS3 in CHY21) were gifts from Dr. Cheol-Sang Hwang. *S. cerevisiae* media included YPD (1% yeast extract, 2% peptone, 2% glucose; only most relevant media components are cited); SD medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose); and synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, plus a drop-out mixture of compounds required by auxotrophic strains). *S. cerevisiae* were transformed with the low copy pCB255, pCB282, pCB284, or pCB285 plasmids using standard techniques (Ausubel et al., 2010). Expression of DHFR-Ub-X-Aβ13myc was induced by growth in SD(-Ura, -Met) for 6 hr at 30°C. 

35S-pulse-chase experiments with *S. cerevisiae* were performed essentially as described previously (Hwang et al., 2009). Transformed yeast strains carrying low copy plasmids expressing test protein fusions were grown in 10 ml of SD(-Ura) medium at 30°C until A600 of ~1.0. Cells were pelleted by centrifugation at 3,000g for 10 min and washed with 0.8 ml of fresh pre-warmed medium. Cell pellets were gently resuspended in 0.4 ml of the same medium but lacking Met/Cys, and incubated for 10 min at 30°C, followed by labeling for 5 min with [35S]L-methionine (0.55 mCi/ml, 1,000 Ci/mmol; MP Biomedicals). Cells were then pelleted by centrifugation and resuspended in 0.4 ml of YPD medium containing cycloheximide at 0.1 mg/ml (chase medium). Samples (0.1 ml) were taken at the indicated time points and added to 0.8 ml of the lysis buffer (1% TritonX-100, 0.15 M NaCl, 5 mM EDTA, 1 mM PMSF (phenylmethylsulfonyl fluoride, freshly dissolved), 50 mM HEPES, pH 7.5) containing “yeast protease inhibitor cocktail” (Roche), followed by rapid freezing in liquid nitrogen. Samples were thawed in thermomixer (Eppendorf) at 37°C for 2 min and thereafter treated by 4 runs in lysing matrix C (0.1 mM silica spheres) using FastPrep-24 (MP Biomedicals) (setting 6.5 m/s, 20 sec, with 2 min on ice between the runs). The resulting samples were centrifuged at 20,000g, and total 35S (in the 10% CCl3COOH-insoluble fraction) in each sample was adjusted, by dilution with lysis buffer, to equalize 35S among different samples. Thus prepared samples were immunoprecipitated using EZview Red anti-cMyc affinity gel. The unbound material was immunoprecipitated using anti-flag M2 magnetic beads. Immunoprecipitated proteins were fractionated by SDS-4-15% PAGE, electrophoretically transferred to PVDF membranes, detected by autoradiography, and quantified, using Storm PhosphorImager and ImageQuant.

**Animal Care and Treatments**
All animal care and procedures were carried out according to the NIH guidelines, and were approved by the Institutional Animal Care and Use Committee and the Office of Laboratory Animal Research (OLAR) at the California Institute of Technology. Mice were housed at ~22°C using a 12 hr light/12 hr dark cycle, with Laboratory Rodent Diet 5001 (PMI International, Richmond, IN) ad libitum. The proteasome inhibitors MG132 (25 μmol/kg) clasto-lactacystin β-lactone (1 μmol/kg), and epoxomicin (0.6 μmol/kg), as well as neprilysin inhibitors Thiorphan (12 mg/kg), Racecadotil (18 mg/kg), and Phosphoramidon (2.5 mg/kg), in addition to verapamil (45 mg/kg), an inhibitor of multidrug resistance transporters, were delivered intraperitoneally (two injections, 12 hrs apart). Twelve hours after the last injection, mouse brains were harvested and proteins were extracted as described below.

**Tissue Extracts and Immunoblotting**
Proteins were extracted from mouse and human brain samples using a three-step sequential procedure. First, brain tissue (225 mg per ml of buffer) was homogenized in TBS buffer (0.15 M NaCl, 50 mM Tris-HCl, pH 7.4) containing “complete protease-inhibitor mixture” (Roche), using FastPrep-24 and Lysing Matrix D (MP Biomedicals), with 3 runs at 6.5 m/s for 30 sec each, and with 5-min incubations on ice between runs. TBS-insoluble material was pelleted by centrifugation at 100,000g for 40 min at 4°C in the TL-100.3 ultracentrifuge. The pellets were washed in TBS, and resuspended in TBS-X (TBS containing 1% Triton-X100) by rotation at 4°C for 30 min TBS-X-insoluble material was precipitated by centrifugation at 100,000g for 40 min at 4°C, washed in TBS, and resuspended in 70% HCOOH (formic acid (FA)), using multiple passages through a 26 gauge needle and overnight rotation 4°C. Material insoluble in 70% HCOOH was pelleted by centrifugation at 22,000g for 10 min at 4°C. Protein concentrations in TBS, TBS-X, and FA extracts were determined using Bio-Rad Protein Assay DyeReagent (BioRad, # 500-0006). HCOOH extracts were additionally dried in a Speed-Vac and washed with acetone. Equal total protein amounts from each sample were fractionated by SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), and proteins were transferred to 0.2 µm nitrocellulose membranes (BioRad, # 162-0112), which were then autoclaved in H₂O to enhance epitope exposure to antibodies (Swerdlow et al., 1986), followed by immunoblotting with the specified antibodies. Detection was carried out using ECL Prime Western blotting Detection System (GE Healthcare, UK) or SuperSignal West Fempto reagents (Thermo Scientific, Rockford, IL) according to manufacturer’s protocol.

**In Vitro Arginylation Assay**
In vitro Ate1 arginyl-transferase (R-transferase) assays were carried out in 50-μl samples largely as described previously (Hu et al., 2006). The samples contained either zero, 0.1, or 1.0 μg of purified recombinant Ate1-1, Ate1-2, Ate1-3, or Ate1-4 mouse transferase (Hu et al., 2006) (Hu et al., 2005) and 0.5 mg/ml of chemically synthesized Aβ42 (Sigma, A9810), total E. coli tRNA (0.6 mg/ml) (Sigma), total E. coli aminoacyl-tRNA synthetases (800 U/ml) (Sigma), 1 mM ATP, 30 mM KCl, 2 mM MgCl₂, 2 mM β-mercaptoethanol, 2 μM L-arginine, 10 mM Tris-HCl (pH 8.0) and 0.1 μM [¹⁴C]L-arginine (PerkinElmer, NEN Radiochemicals, Waltham, MA). A reaction mixture (50 μl) was incubated for 30 min at 37°C, followed by the addition of the equal volume of 2xSDS sample buffer. Samples were then heated at 95°C for 10 min, followed by SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), electrophoretic transfer to 0.2 μm PVDF membranes using the iBlot apparatus (Invitrogen), and both autoradiography and immunoblotting, as described in the legend to Figure 4D.
**Antibody Specific for Arg-Asp-Aβ**

Rabbit peptide-mediated antibody to RDAEFRHDSGYC, the Nt-arginylated N-terminal sequence of Aβ42 (except for C-terminal Cys, which was used to conjugate the peptide to keyhole limpet hemocyanin, a carrier protein) was produced by Abgent (San Diego, CA), using standard methods. The peptides RDAEFRHDSGYC and its “non-arginylated” counterpart DAEFRHDSGYC were synthesized and purified also by Abgent. The resulting antibody (its IgG fraction, produced using immobilized Protein A) was affinity-purified, “positively” at first, against the immobilized RDAEFRHDSGYC peptide. The peptide-bound antibody was eluted and thereafter “negatively” purified against the DAEFRHDSGYC peptide (immobilized using SulfoLink Coupling Resin (Pierce)), with collection, this time, of the unbound antibody fraction. The resulting antibody was characterized as described in Figure 5A and the main text, and was then used to detect Nt-arginylated Arg-Asp-Aβ42. Immunoblotting was carried out (with the antibody at 1 μg/ml) overnight at 4°C in 5% skim milk in TBS-T (TBS containing 0.1% Tween-20). Goat anti-rabbit secondary antibody conjugated to horseradish peroxidase was used at 1:2,000 dilution, and detection was performed using one of the two above-described chemiluminescence systems.
<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Description</th>
<th>Source or Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>pcDNA3.0-Neo</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; Expression vector for cloning your gene of interest</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>pGL3-Control</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; luciferase reporter driven by SV40 promoter. Also contains the SV40 enhancer.</td>
<td>Promega</td>
</tr>
<tr>
<td>pAF6a-13myc-kanMX6</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Kan&lt;sup&gt;R&lt;/sup&gt;; Yeast genomic targeting</td>
<td>Addgene</td>
</tr>
<tr>
<td>pCH280</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pRS416MET25-&lt;sup&gt;f&lt;/sup&gt;DHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-MGT1&lt;sup&gt;f&lt;/sup&gt;</td>
<td>(Hwang et al., 2009)</td>
</tr>
<tr>
<td>pKP551</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Trp, pBAM- Ub&lt;sup&gt;K48R&lt;/sup&gt;-eK-mCherry-Flag-Myc.</td>
<td>This study</td>
</tr>
<tr>
<td>IMAGE clone: 5287266</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; 3’ full length human α-synuclein cDNA</td>
<td>Open Biosystems</td>
</tr>
<tr>
<td>Clone: LIFESEQ2505218</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; full length human TDP43 cDNA</td>
<td>Open Biosystems</td>
</tr>
<tr>
<td>Clone: LIFESEQ6770882</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; 5’ portion of human Tau-1N cDNA (lacking exon 3)</td>
<td>Open Biosystems</td>
</tr>
<tr>
<td>pCB253</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Kan&lt;sup&gt;R&lt;/sup&gt;; pAF6a-13myc-kanMX6 containing Aβ42-13myc tag</td>
<td>This study</td>
</tr>
<tr>
<td>pCB255</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pRS416MET25-&lt;sup&gt;f&lt;/sup&gt;DHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Aβ42&lt;sup&gt;13myc&lt;/sup&gt;</td>
<td>This study</td>
</tr>
<tr>
<td>pCB268</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Aβ42&lt;sup&gt;13myc&lt;/sup&gt; under the control of T7 or CMV promoter</td>
<td>This study</td>
</tr>
<tr>
<td>pCB282</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pRS416MET25-&lt;sup&gt;f&lt;/sup&gt;DHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Val-Aβ42&lt;sup&gt;13myc&lt;/sup&gt;</td>
<td>This study</td>
</tr>
<tr>
<td>pCB284</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pRS416MET25-&lt;sup&gt;f&lt;/sup&gt;DHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Arg-Asp-Aβ42&lt;sup&gt;13myc&lt;/sup&gt;</td>
<td>This study</td>
</tr>
<tr>
<td>pCB285</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pRS416MET25-&lt;sup&gt;f&lt;/sup&gt;DHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Met-Aβ42&lt;sup&gt;13myc&lt;/sup&gt;</td>
<td>This study</td>
</tr>
<tr>
<td>pCB322</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R&lt;/sup&gt;-Arg208-TDP43&lt;sup&gt;f&lt;/sup&gt; under the control of T7 or CMV promoter</td>
<td>This study</td>
</tr>
<tr>
<td>pCB323</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid</td>
<td>This study</td>
</tr>
</tbody>
</table>
encoding $^{f}$DHFR-Ub$^{K48R}$-Met208-TDP43$^{f}$
under the control of T7 or CMV promoter

pCB324 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Gln208-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB325 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Glu208-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB326 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Asp219-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB327 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Gln219-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB328 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Val219-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB329 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-ArgAsp219-
TDP43$^{f}$ under the control of T7 or CMV promoter

This study

pCB330 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Asp247-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB331 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Gln247-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB332 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Val247-TDP43$^{f}$
under the control of T7 or CMV promoter

This study

pCB333 Amp$^{R}$; Neo$^{R}$; pcDNA3.0-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-ArgAsp247-
TDP43$^{f}$ under the control of T7 or CMV promoter

This study

pCB334 Amp$^{R}$; pGL3-Control-based plasmid encoding $^{f}$DHFR-Ub$^{K48R}$-Asp219-TDP43$^{f}$
under the control of SV40 promoter

This study
<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pCB336</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pGL3-Control-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Val219-TDP43&lt;/sup&gt;f under the control of SV40 promoter</td>
</tr>
<tr>
<td>pCB338</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pGL3-Control-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Asp247-TDP43&lt;/sup&gt;f under the control of SV40 promoter</td>
</tr>
<tr>
<td>pCB340</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pGL3-Control-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Val247-TDP43&lt;/sup&gt;f under the control of SV40 promoter</td>
</tr>
<tr>
<td>pCB341</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pGL3-Control-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-ArgAsp247-TDP43&lt;/sup&gt;f under the control of SV40 promoter</td>
</tr>
<tr>
<td>pCB347</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Gln79-αSyn&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB348</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Val79-αSyn&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB383</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Glu3-Tau-2N3-124&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB385</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Val3-Tau-2N3-124&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB386</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Glu3-Tau-1N95&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB388</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; Neo&lt;sup&gt;R&lt;/sup&gt;; pcDNA3.0-based plasmid encoding fDHFR-Ub&lt;sup&gt;K48R-Val3-Tau-1N95&lt;/sup&gt;f under the control of T7 or CMV promoter</td>
</tr>
<tr>
<td>pCB400</td>
<td>Amp&lt;sup&gt;R&lt;/sup&gt;; pGL3-Control-based plasmid encoding mCherry-Ub&lt;sup&gt;K48R-Asp247-TDP43&lt;/sup&gt;f under the control of SV40 promoter</td>
</tr>
</tbody>
</table>

This study
<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer’s sequence (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB268</td>
<td>ATATGAGGTTCATCATCAAAAAATTTGTTTCTTTTGCTGAA</td>
</tr>
<tr>
<td>CB269</td>
<td>GATGTGGGTGTTCAACAAGAGGTGCGATCATTGGACTCTAGG</td>
</tr>
<tr>
<td>CB270</td>
<td>TGGGCAGGTGTTCATACGCTGCTGTTCCGACTACAAGGA</td>
</tr>
<tr>
<td>CB271</td>
<td>CGATGATGACAAAGTAAAGGTAATCCGTAC</td>
</tr>
<tr>
<td>CB272</td>
<td>TTTGATGATGAACCTCATATCCAGAATCATGTCGGAACCT</td>
</tr>
<tr>
<td>CB273</td>
<td>CTTTTTTGTAACCCACATCTCTCAGGAAGACACACAAATT</td>
</tr>
<tr>
<td>CB274</td>
<td>CGCTATGACAAACCCGCCACCATTGAGCTCAAATGATCGCA</td>
</tr>
<tr>
<td>CB275</td>
<td>GATCGAATTICTACTTGTACATCTCGTCCTTGAGTGTCGGAACCAAGA</td>
</tr>
<tr>
<td>CB280</td>
<td>GATCGGGCCCTCTCAGATCATTGTCATCGTCTCCTTG</td>
</tr>
<tr>
<td>CB302</td>
<td>GATCGGATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB304</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB313</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB314</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB316</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB320</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB321</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB322</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB323</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB327</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB329</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB330</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB331</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB332</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB333</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB334</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB335</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB336</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB337</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
<tr>
<td>CB364</td>
<td>GATCCCGCGGCTGCTGACAGATGTCGTAAGAGGTGCCAGG</td>
</tr>
</tbody>
</table>
CB365  GAATCCGCGGTGGTGAAGACAGTGGAGGGAGCAGGG
CB367  GAATCCCGGGGGCTTCAGGTTCGTAGTCTTG
CB373  GAATCCGCGGTGGTGAGCCAAGACAGGAGTTTGAGATGAG
CB375  GAATCCGCGGTGGTGTGCCAAGACAGGAGTTTGAGATGAG
CB377  GATCTCTAGATTACTTGTCATCGTCATCCTTTGTAGTCAGACCCGGGTTGGGTCACGTGACCAGCAGC
CB379  GGGGCTGCGCGGCAGCCTGCTTGCCGGGAGCTCCCTACATCTTCCGCTGTTGGAGTGCTC
CB380  GCTCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAAGAAGCA
CB383  GATCAAGCTTCCCACCATGGTGAGCAAGGGCGAGGAGG
CB384  GATCAACCGGTCAAGGTCTTTGACGAAAATCTGCATGGTCAAGGACCCACACGCTTGACCTCATG GCC
SUPPLEMENTAL REFERENCES

Arnesen, T., Van Damme, P., Polevoda, B., Helsens, K., Evjenth, R., Colaert, N., Varhaug, J.E.,
reveal the evolutionary conservation and divergence of N-terminal acetyltransferases
from yeast to humans. Proc Natl Acad Sci USA 106, 8157-8162.

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Smith, J.A., Seidman, J.G., and Struhl,

pathway: loss of fat, higher metabolic rate, damaged spermatogenesis, and neurological

Caprio, M.A., Sambrooks, C.L., Durand, E.S., and Hallak, M. (2010). The arginylation-
dependent association of calreticulin with stress granules is regulated by calcium.
Biochem J 429, 63-72.

Cauwe, B., and Opdenakker, G. (2010). Intracellular substrate cleavage: a novel dimension in the


Structural basis for the recognition of N-end rule substrates by the UBR box of ubiquitin


ubiquitin ligase Ubr1. FEBS Lett 582, 4143-4146.

a WD repeat protein required for ubiquitin-mediated proteolysis in Saccharomyces
cerevisiae. EMBO J 15, 4884-4899.


degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proc Natl Acad Sci USA 107, 1106-1111.

Horowitz, P.M., Patterson, K.R., A.L., G.-B., Reynolds, M.R., Carroll, C.A., Weintraub, S.T.,


rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature 437, 981-986.


